Nektar Therapeutics (NKTR)

[dangerx]

Great DD here, Surf! The two drug candidates currently in clinical trials and the 124 million dollar deal for the royalties on Cimzia and Mircera have made this long term biotech gamble a lot more appealing. Corporate updates for the BEACON phase III trial for NKTR-102 can be found on the company's website: http://www.nektar.com/product_pipeline/oncology_nktr-102.html and the NIH information on the status of the clinical trial can be found here: http://clinicaltrial.gov/ct2/show/NCT01492101?term=BEACON&rank=2

It may be a little early to buy and hold, though... the primary outcome for the BEACON trial is overall survival after 36 months, and the trial is still recruiting new patients, but from what I can tell, the current financials look good for a biotech company (increased rev on sales and licensing of their technology platform, increased assets from the sale of royalties). If any seasoned trader has an eye on this company, could you please share what you're seeing from a technical analysis view point? My background is in pharmacy, not business, but if near-dollar swings are gonna be the norm with this stock, it could be fun to play with until the results from the clinical trials are announced.